Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 221

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 221
---
 operating assets and liabilities (note 20)                      (2,514   )                  58                    (936   )
Net cash provided by (used in) operating activities                       (14,568   )              (2,582   )               5,229    
Cash flows from financing activities                                                                                                 
Exercise of stock options                                                       -                      13                      63    
Payments on exercise of DSUs                                                 (167   )                   -                       -    
Payments on lease liabilities                                                (421   )                (370   )                (330   )
Net cash used in financing activities                                        (588   )                (357   )                (267   )
Cash flows from investing activities                                                                                                 
Cash acquired on acquisition of Aeterna Zentaris Inc. (note 5)             26,037                       -                       -    
Purchase of property and equipment                                         (1,161   )                (722   )                (304   )
Changes in restricted cash equivalents                                        207                      (8   )                   -    
Net cash provided by (used in) investing activities                        25,083                    (730   )                (304   )
Effect of exchange rate changes on cash and cash equivalents                 (212   )                 157                    (625   )
Net change in cash and cash equivalents                                     9,715                  (3,512   )               4,033    
Cash and cash equivalents – beginning of year                               6,678                  10,190                   6,157    
Cash and cash equivalents – end of year                                    16,393                   6,678                  10,190    
 
The accompanying notes are an integral part of these consolidated financial statements.
 

F-10
----
COSCIENS Biopharma Inc.
 Notes to Consolidated Financial Statements
 As of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022
 
(in thousands of US dollars, except share and per share data and where otherwise noted)
 

1.   Business
     overview
-------------
 
Summary of business
 
COSCIENS Biopharma Inc. and its subsidiaries (the “Company”), formerly Aeterna Zentaris Inc., is a Life Science company developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. These products are produced using the Company’s proprietary technologies. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX